August 2, 2017 03:10 PM EDT

FDA experts turn thumbs down on J&J’s troubled rheumatoid arthritis drug sirukumab

John Carroll

Editor & Founder

Faced with a big red flag regulators raised on safety, a panel of outside experts turned thumbs down on approving J&J’s sirukumab for rheumatoid arthritis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA experts turn thumbs down on J&J’s troubled rheumatoid arthritis drug sirukumab

John Carroll

Editor & Founder

Sign up to read this article for free.

A look at biotech's year of the megaround

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

Flagship biotech Valo Health ends 2024 with mid-stage fail

FDA ex­perts turn thumbs down on J&J’s trou­bled rheuma­toid arthri­tis drug sirukum­ab

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

FDA experts turn thumbs down on J&J’s troubled rheumatoid arthritis drug sirukumab

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

Flagship biotech Valo Health ends 2024 with mid-stage fail